PDCD1 and melanoma: Indeed, resistance to T cell-mediated immunotherapy was stated as a possible consequence of the loss of PTEN, which was reported to correlate with decreased T-cell infiltration at tumor sites and with a worse outcome in melanoma patients treated with anti PD-1.